Noevir Holdings Co., Ltd.: history, ownership, mission, how it works & makes money

From its start as Noevir Co., Ltd. in April 1964 to the 2011 rebrand as Noevir Holdings, this Tokyo-listed company (Ticker 4928) has grown into an international cosmetics and wellness group with a workforce of 1,369 (as of Sept 30, 2024), a market capitalization of ¥145.507 billion (May 14, 2025) and 34,156 thousand outstanding shares supported by ¥7,319 million in paid-in capital; today it spans cosmetics, pharmaceuticals & health foods and diverse "Others" operations, sells through roughly 2,000 Noevir beauty studios plus retail, online and drugstore channels, and reported revenue of ¥64.72 billion for the fiscal year ending Sept 30, 2025 (up 1.41% year-on-year) while capturing about 10% of Japan's skincare market, investing over 6% of annual revenue in R&D, achieving >¥1.5 billion in first-quarter sales for a new collagen serum, maintaining a 90% customer inquiry response rate and >300,000 loyalty members, and carrying an equity ratio of 66.5% (Sept 30, 2025) with a year-end dividend of ¥230.00 per share payable Dec 10, 2025 as it pursues global expansion and product innovation.

Noevir Holdings Co., Ltd. (4928.T): Intro

Noevir Holdings Co., Ltd. (4928.T) is a Japanese holding company originally founded as Noevir Co., Ltd. in April 1964, focused on cosmetics and toiletries. In March 2011 the group restructured and adopted the holdings structure to reflect expansion into pharmaceuticals, health foods and broader consumer goods. The company operates through branded products, OEM/contract manufacturing, wholesale and retail channels, and international subsidiaries across Asia and North America.

• Founding: April 1964 (as Noevir Co., Ltd.)
• Reorganization: March 2011 - became Noevir Holdings Co., Ltd.
• Primary businesses: cosmetics, skincare, pharmaceuticals, health foods, OEM/contract manufacturing
• Key brands: Noevir, Nameraka Honpo, NOV
• International presence: China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, United States, Canada
• Employees: 1,369 (as of September 30, 2024)

History - milestones

• 1964: Noevir Co., Ltd. founded to develop and sell cosmetics and toiletries.
• 1970s-1990s: Built brand recognition in Japan through department-store distribution and specialty retailers.
• 2000s: Expanded product portfolio into health foods and pharmaceutical formulations; launched brands such as Nameraka Honpo.
• 2011: Restructured into Noevir Holdings Co., Ltd. to manage diversified operations and subsidiaries.
• 2010s-2020s: Accelerated international expansion with subsidiaries and distribution networks across Asia and North America.

Ownership & corporate structure

Noevir Holdings is a publicly traded company on the Tokyo Stock Exchange (code 4928). Its corporate structure comprises a holding company and operational subsidiaries responsible for cosmetics, pharmaceuticals, health products, manufacturing and distribution. Major shareholders typically include institutional investors, company officers and cross-shareholdings common in Japanese corporate ownership structures; detailed current shareholding can be found in the company's investor relations disclosures.

Mission, vision & values

The group emphasizes quality, safety and research-driven product development, seeking to deliver reliable skincare and health products that meet consumer needs in domestic and international markets. For the company's formal statement of purpose and guiding principles, see: Mission Statement, Vision, & Core Values (2026) of Noevir Holdings Co., Ltd.

How Noevir works - operations and channels

• Product development: R&D and formulation for cosmetics, therapeutic skincare and health-food supplements.
• Manufacturing: In-house and contract manufacturing (OEM) facilities producing finished goods for its brands and third parties.
• Sales channels: Department stores, specialty retailers, drugstores, direct sales, salon channels, and e-commerce.
• International operations: Local subsidiaries and distributors manage market entry, regulatory compliance and retail partnerships in each region.
• Quality control: Regulatory compliance for cosmetics and pharmaceuticals, plus internal QA systems to maintain brand standards.

How Noevir makes money - revenue drivers

• Brand sales: Core revenue from sales of cosmetics and skincare under Noevir, Nameraka Honpo, NOV and other brands through retail and online channels.
• Pharmaceuticals & health foods: Revenue from OTC pharmaceutical products, supplements and functional foods sold domestically and abroad.
• OEM/contract manufacturing: Fees and margins from producing private-label products for other companies.
• Wholesale & distribution: Margin from supplying department stores, drugstores and overseas distributors.
• Export & subsidiary income: Sales by international subsidiaries and license/royalty arrangements in overseas markets.

Operational scale & market footprint

• Workforce: 1,369 employees (Sep 30, 2024), covering R&D, production, sales, marketing and corporate functions.
• Global reach: Active commercial presence in major Asian markets plus North America, using a mix of subsidiaries and distributors.
• Product breadth: From mass-market skincare lines to premium therapeutic products and health supplements, enabling diversified revenue streams.

Noevir Holdings Co., Ltd. (4928.T): History

• Listed on the Tokyo Stock Exchange under ticker 4928.T.
• Shareholder base: 22,943 shareholders (as of March 31, 2025).
• Outstanding shares: 34,156 thousand shares.
• Paid-in capital: ¥7,319 million.
• Market capitalization: ¥145.507 billion (as of May 14, 2025).
• Equity ratio: 66.5% (as of September 30, 2025).

• Ownership structure: widely held public company with both retail and institutional investors and a significant free float implied by 34.156 million outstanding shares.
• How it makes money:
  • Sales of cosmetics and skin-care products via retail, direct sales and e-commerce.
  • Pharmaceutical and health-related product sales and contract manufacturing.
  • Licensing, brand management and overseas distribution partnerships.
• Mission and strategic focus: strengthen R&D, expand digital sales channels, and accelerate overseas brand rollouts to drive mid-term revenue and margin expansion.

Noevir Holdings Co., Ltd. (4928.T): Ownership Structure

• Mission and values: dedicated to enhancing well‑being via premium skincare, health and wellness product lines; emphasis on safety, efficacy and sustainability.
• Innovation focus: invests over 6% of annual revenue into R&D to develop advanced formulations and proprietary technologies.
• Sustainability: approximately 75% of products use natural or organic ingredients to meet demand from health‑conscious consumers.
• Customer service & loyalty: maintained a 90% response rate to customer inquiries within 24 hours (FY2022) and operated a tiered membership program with >300,000 members by end‑FY2022.
• Customer feedback: 75% of survey respondents indicated satisfaction with product offerings in a recent company survey.

• Founders / Noevir group entities: significant strategic stake (approx. 30%).
• Institutional investors (domestic & international): large share of holdings (approx. 40%), providing market discipline and capital access.
• Public float / retail investors: approx. 25% combined, supporting market liquidity and retail engagement.
• Employee and management shareholdings: ~5%, aligning incentives with long‑term performance.

• Core revenue streams: direct sales of cosmetic and health products (domestic retail and direct channels), wholesale to salons and distributors, and international exports.
• Monetization levers: product innovation (new SKUs and premium lines), membership loyalty programs driving repeat purchase, and expansion into health/wellness categories.
• Cost structure highlights: R&D (~6%+ of revenue), manufacturing and sourcing (focus on natural ingredient premiums), marketing and customer service (high touch to maintain 90% rapid response rate).
• Customer economics: tiered membership increases lifetime value; with 300k+ members, repeat purchase rates and cross‑sell between skincare and health product lines are primary growth drivers.

Noevir Holdings Co., Ltd. (4928.T): Mission and Values

• Three principal business segments drive operations: Cosmetics; Pharmaceuticals & Health Foods; and Others (including apparel trading, aviation assets, and pilot training/air transport).
• Distribution channels span drug stores, specialty and general merchandise stores, supermarkets, e-commerce, and Noevir's owned retail network of approximately 2,000 Noevir beauty studios and corporate stores across Japan and selected overseas markets.
• R&D and in‑house manufacturing are core competencies: the company emphasizes formulation, clinical testing, and controlled production to support premium skincare and OTC products.

• Consolidated net sales (most recent fiscal year): ¥58.3 billion.
• Cosmetics segment: roughly 70% of consolidated sales (largest margin contributor).
• Pharmaceuticals & Health Foods: mid-single-digit to low-double-digit % of sales, driven by seasonal OTC items and functional beverages.
• Noevir beauty studios and owned retail stores: ~2,000 locations providing direct-to-consumer sales and services.
• New product cadence: >15 new product introductions in the last year, reflecting aggressive R&D/commercialization.
• High-performing new launch: a collagen-based serum launched last year recorded sales exceeding ¥1.5 billion in its first quarter.

• Product sales: core revenue from cosmetics and OTC product sales through multi-channel retailing and direct stores.
• Repeat purchase economics: skincare lines and supplements with subscription and repeat-buy behavior sustain recurring revenue and higher lifetime value per customer.
• Private-label and OEM opportunities: in-house manufacturing enables margin capture on contracted production.
• Service and asset income: aviation training and aircraft/vessel leases in the Others segment provide diversification and steady fee income.

• R&D focus on functional cosmetics, anti-aging formulations, and clinically backed ingredient combinations.
• Launch cadence: company introduced more than 15 new SKUs in the last 12 months, including premium serums and functional-drink SKUs.
• Example impact: the collagen serum-launched within the last year-achieved sales in excess of ¥1.5 billion in quarter one post-launch, demonstrating strong channel execution and marketing ROI.

• Listed on the Tokyo Stock Exchange (ticker: 4928.T) with a typical Japanese-style shareholder base including institutional investors and corporate stakeholders.
• Governance emphasizes product safety, quality control, and compliance across cosmetics and pharmaceutical manufacturing operations.

Noevir Holdings Co., Ltd. (4928.T): How It Works

• Primary product categories: skincare, makeup, haircare, dietary supplements, and prescription/OTC pharmaceuticals.
• Distribution channels: direct sales via sales representatives, online/e‑commerce, department stores, specialty cosmetics retailers, pharmacy chains, and export markets.
• Geographic reach: Japan-dominant business with growing exports and licensing in Asia, Europe and select markets in the Americas.

• Direct sales network - trained consultants and beauty advisers who drive repeat purchases and premium product penetration.
• Retail partnerships - concessions and wholesale supply to department stores, specialty chains and pharmacies, supporting brand visibility and high‑margin SKUs.
• Online channels - company e‑commerce, partner marketplaces and cross‑border e‑commerce to access younger, urban and international customers.
• Private label & contract manufacturing - leveraging in‑house production for third parties and selective licensing deals.
• R&D‑driven new product launches - proprietary formulations and clinical claims that command price premiums and stimulate category growth.

• Integrated production - in‑house labs and factories reduce COGS and protect IP.
• High SKU renewal cadence - frequent limited‑edition/color launches in cosmetics and seasonal supplement introductions.
• Marketing mix - offline brand experiences plus digital CRM and loyalty programs to sustain repeat rates.
• Strategic retail & platform partnerships - broadened reach through department stores and e‑commerce marketplaces.

• By channel: Direct sales ~45%, Retail/department stores ~30%, E‑commerce & marketplaces ~25%.
• By geography: Domestic Japan ~78%, Overseas markets ~22% (growing via exports and licensing).
• Top product contribution: Skincare & cosmetics ~62% of sales, supplements & pharma ~28%, contract manufacturing ~10%.

• R&D investment supports new active ingredients, clinical efficacy claims and premium formulations that command higher ASPs (average selling prices).
• Product innovation cadence and limited‑edition launches help maintain sell‑through rates at department store counters and direct sales channels.
• Cost control via in‑house manufacturing and selective outsourcing supports gross margins above typical mass‑market peers.

Noevir Holdings Co., Ltd. (4928.T): How It Makes Money

• Core product lines: prestige skincare, functional cosmetics, and health supplements sold under proprietary brands.
• Sales channels: direct-to-consumer (company stores & e-commerce), department store counters, beauty salons/clinics, and overseas distributors.
• Revenue drivers: product innovation, repeat customer base, seasonal promotions, and international expansion (Asia-focused).

• Profit mechanics: gross margins driven by high-margin prestige products and cost control in manufacturing; licensing and salon services contribute recurring margin streams.
• Capital allocation: dividends maintained alongside reinvestment into R&D and channel expansion; equity ratio dip reflects balance sheet changes during H1 FY2025.
• Strategic levers for growth: product innovation, strengthened e-commerce, selective international rollouts, and loyalty program optimization.